Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2016

View Archived Issues

Clinical safety and pharmacodynamics of VLX-103 in cirrhotic patients with early-stage HCC

Promising clinical data for TS-23 supports future development in thrombotic vascular diseases

FDA grants orphan drug designation to Genexine's GX-H9

Imara doses first volunteer in IMR-687 phase I trial

ALD-1910 induces photophobia in WT CT1 mice

Sorrento's TNK Therapeutics signs binding term sheet to acquire Virttu Biologics

EMA grants PRIME to SAGE-547 for postpartum depression

Genexine signs agreement with Merck & Co.

Cuvitru now available in U.S. for patients with primary immunodeficiency

LLS commits USD 40.3 million to fund new research into hematologic cancers

AstraZeneca announces completion of MEDI-2070 outlicensing agreement with Allergan

GTx to advance enobosarm phase II trial to final stage

Grunenthal acquires Thar Pharmaceutical

Tianjin Institute of Pharmaceutical Research patents URAT1 inhibitors

FDA grants fast track designation to crenolanib for GIST

Concert Pharmaceuticals discloses OTX-015 analogues

Daewoong Pharmaceutical describes ATPase inhibitors and/or 5-HT2A and/or M1 and/or M2 antagonists

Agilis Biotherapeutics treats first patient in phase IIb study of AGIL-AADC

Novartis reports promising topline results from STRIVE trial of AMG-334 in episodic migraine

Japanese researchers develop antimalarial agents

Chinese scientists present FXR agonists

Gilead reports topline results from phase III trials of momelotinib in myelofibrosis

Antidepressant effects of SUVN-1507035 in animal models of psychosis

CTC biomarker identifies CRPC patients likely to respond to PARP inhibitor treatment

Sofosbuvir, ledipasvir and ribavirin give high cure rates in drug users with hepatitis C

DSMB recommends continuation of phase III study of PXT-003 for CMT1A

Pfizer initiates phase I trial of PF-06747143 in AML

CD40L-encoding adenovirus enhances dendritic cell therapy for cancer

EMA grants positive opinion for teriparatide biosimilar

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...